These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 222442)

  • 1. Study of the cytotoxicity and metabolism of 4-amino-3-carboxamido-1-(beta-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine using inhibitors of adenosine kinase and adenosine deaminase.
    Wotring LL; Townsend LB
    Cancer Res; 1979 Aug; 39(8):3018-23. PubMed ID: 222442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
    Cass CE; Tan TH; Selner M
    Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of adenosine deaminase by deaza derivatives of adenosine and purine riboside.
    Lupidi G; Riva F; Cristalli G; Grifantini M
    Ital J Biochem; 1982; 31(6):396-403. PubMed ID: 7184903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of 2'-deoxycoformycin-inhibited adenosine deaminase of mouse erythrocytes and leukemia L1210 in vivo.
    Agarwal RP
    Cancer Res; 1979 Apr; 39(4):1425-7. PubMed ID: 421226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin.
    Cass CE; Selner M; Tan TH; Muhs WH; Robins MJ
    Cancer Treat Rep; 1982 Feb; 66(2):317-26. PubMed ID: 6976834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
    Cass CE; Selner M; Phillips JR
    Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia.
    Lee SH; Caron N; Kimball AP
    Cancer Res; 1977 Jul; 37(7 Pt 1):1953-5. PubMed ID: 861931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial rate kinetics of the transport of adenosine and 4-amino-7-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (tubercidin) in cultured cells.
    Harley ER; Paterson AR; Cass CE
    Cancer Res; 1982 Apr; 42(4):1289-95. PubMed ID: 7060008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
    Plunkett W; Cohen SS
    Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
    Matsushita T; Ryu EK; Hong CI; MacCoss M
    Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis of 1-beta-D-ribofuranosyl-1,2-dihydropyrimidin-2-one derivatives and their biological activities.
    Maeda M; Kaneko C; Uchida NA; Sasaki T
    Nucleic Acids Symp Ser; 1985; (16):77-80. PubMed ID: 4088888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
    Bontemps F; Van den Berghe G
    Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins.
    Firestein GS; Bullough DA; Erion MD; Jimenez R; Ramirez-Weinhouse M; Barankiewicz J; Smith CW; Gruber HE; Mullane KM
    J Immunol; 1995 Jan; 154(1):326-34. PubMed ID: 7527814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological activity of pyrazolo[3,4,-d]pyrimidine nucleosides and nucleotides related to tubercidin, toyocamycin, and sangivamycin.
    Hecht SM; Frye RB; Werner D; Fukui T; Hawrelak SD
    Biochemistry; 1976 Mar; 15(5):1005-15. PubMed ID: 766833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
    Eldrup AB; Prhavc M; Brooks J; Bhat B; Prakash TP; Song Q; Bera S; Bhat N; Dande P; Cook PD; Bennett CF; Carroll SS; Ball RG; Bosserman M; Burlein C; Colwell LF; Fay JF; Flores OA; Getty K; LaFemina RL; Leone J; MacCoss M; McMasters DR; Tomassini JE; Von Langen D; Wolanski B; Olsen DB
    J Med Chem; 2004 Oct; 47(21):5284-97. PubMed ID: 15456273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE; Au-Yeung TH
    Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and biological properties of 5-bromotubercidin: differential effects on cellular DNA-directed and viral RNA-directed RNA synthesis.
    Brdar B; Reich E
    Bioorg Med Chem; 2008 Feb; 16(3):1481-92. PubMed ID: 17977728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy.
    Wiesner JB; Ugarkar BG; Castellino AJ; Barankiewicz J; Dumas DP; Gruber HE; Foster AC; Erion MD
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1669-77. PubMed ID: 10336567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.